20/20 Biolabs annual free cash flow
2023
20/20 Biolabs Free Cash Flow (FCF) History (AIDX)
20/20 Biolabs reported −$4.5M in free cash flow for fiscal 2023, a free cash flow margin of −317.61%.
View full 20/20 Biolabs company overview20/20 Biolabs free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2023 | 2023-12-31 | −$4.5M | — | — | −317.61% |
20/20 Biolabs quarterly free cash flow
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$605,460 | — | — | −82.87% |
| Q1 2026 | 2026-03-31 | −$1.3M | — | — | −366.27% |
20/20 Biolabs free cash flow growth trends
20/20 Biolabs's latest reported quarter, Q2 2026, generated −$605,460 in free cash flow.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review 20/20 Biolabs source filings ↗